The FDA’s advisory board is considering to approve the Biogen’s Aducanumab for Alzheimer’s therapy, again, after years “reorganizing” the clinical data.

One says the possible mechanism is to help open the canal for garbage plaque to leave the brain, different from the other explanation such as of Eli Lily’s.

According to the prediction of Free Energy and Memory Protein Stability theory, just let the plaque proteins leave the brain, one can’t stop the memory protein loss. Thus Aducanumab will not stop the deterioration of early and middle stage Alzheimer’s disease.

Let’s see.